Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Mismatch-repair-deficient colorectal cancers frequently harbor BRAF V600E mutations.
• Monotherapy with BRAF inhibitors has shown limited clinical utility in this context.
• Tumor resistance to BRAF inhibitors is often linked to upregulated epidermal growth factor receptor (EGFR) signaling.

Purpose of the Study:

• To investigate the clinical utility of dual-targeted therapy inhibiting both BRAF and EGFR in a heavily pretreated patient with colorectal cancer.
• To assess the tolerance and clinical benefit of off-label combination therapy.

Main Methods:

• Case report of a heavily pretreated patient with colorectal cancer.
• Administration of off-label dual-targeted therapy combining BRAF and EGFR inhibitors.
• Clinical course monitoring for tolerance and efficacy.

Main Results:

• The patient received the dual-targeted therapy with good tolerance.
• Apparent clinical benefit was observed during the treatment course.
• This suggests a potential therapeutic strategy for refractory colorectal cancer.

Conclusions:

• Dual inhibition of BRAF and EGFR may offer a viable treatment option for patients with refractory colorectal cancer.
• This approach warrants further investigation in clinical trials.
• Combination therapy could overcome resistance mechanisms associated with BRAF inhibition.